S. Lovestone, A. Guntert, A. Hye, S. Lynham, M. Thambisetty et al., Proteomics of Alzheimer???s disease: understanding mechanisms and seeking biomarkers, Expert Review of Proteomics, vol.4, issue.2, pp.227-238, 2007.
DOI : 10.1586/14789450.4.2.227

H. Hampel, G. Wilcock, S. Andrieu, P. Aisen, K. Blennow et al., Biomarkers for Alzheimer's disease therapeutic trials, Progress in Neurobiology, vol.95, issue.4, pp.579-593, 2011.
DOI : 10.1016/j.pneurobio.2010.11.005

K. Blennow, H. Hampel, M. Weiner, and H. Zetterberg, Cerebrospinal fluid and plasma biomarkers in Alzheimer disease, Nature Reviews Neurology, vol.359, issue.3, pp.131-144, 2010.
DOI : 10.1038/nrneurol.2010.4

N. Verwey, W. Van-der-flier, K. Blennow, C. Clark, S. Sokolow et al., A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease, Annals of Clinical Biochemistry, vol.46, issue.3, pp.46235-240, 2009.
DOI : 10.1258/acb.2009.008232

M. Thambisetty and S. Lovestone, Blood-based biomarkers of Alzheimer???s disease: challenging but feasible, Biomarkers in Medicine, vol.4, issue.1, pp.65-79
DOI : 10.2217/bmm.09.84

M. Thambisetty, R. Tripaldi, J. Riddoch-contreras, H. A. An, Y. Campbell et al., Proteome-Based Plasma Markers of Brain Amyloid-?? Deposition in Non-Demented Older Individuals, Journal of Alzheimer's Disease, vol.22, issue.4, pp.1099-1109, 2010.
DOI : 10.3233/JAD-2010-101350

M. Thambisetty, A. Simmons, L. Velayudhan, H. A. Campbell, J. Zhang et al., Association of Plasma Clusterin Concentration With Severity, Pathology, and Progression in Alzheimer Disease, Archives of General Psychiatry, vol.67, issue.7, pp.67739-748, 2010.
DOI : 10.1001/archgenpsychiatry.2010.78

J. Klein, S. Jupp, P. Moulos, M. Fernandez, B. Buffin-meyer et al., The KUPKB: a novel Web application to access multiomics data on kidney disease, The FASEB Journal, vol.26, issue.5, pp.2145-2153
DOI : 10.1096/fj.11-194381

URL : https://hal.archives-ouvertes.fr/inserm-00726822

D. Fourches, J. Barnes, N. Day, P. Bradley, J. Reed et al., Cheminformatics Analysis of Assertions Mined from Literature That Describe Drug-Induced Liver Injury in Different Species, Chemical Research in Toxicology, vol.23, issue.1, pp.171-183, 2010.
DOI : 10.1021/tx900326k

S. Lovestone, P. Francis, I. Kloszewska, P. Mecocci, A. Simmons et al., AddNeuroMed-The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease, Annals of the New York Academy of Sciences, vol.13, issue.2, pp.36-46, 2009.
DOI : 10.1111/j.1749-6632.2009.05064.x

A. Simmons, E. Westman, S. Muehlboeck, P. Mecocci, B. Vellas et al., The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease : experience from the first 24 months, International Journal of Geriatric Psychiatry, vol.21, issue.1, pp.75-82, 2011.
DOI : 10.1002/gps.2491

A. Simmons, E. Westman, S. Muehlboeck, P. Mecocci, B. Vellas et al., MRI Measures of Alzheimer's Disease and the AddNeuroMed Study, Annals of the New York Academy of Sciences, vol.24, issue.4, pp.47-55, 2009.
DOI : 10.1111/j.1749-6632.2009.05063.x

E. Westman, A. Simmons, J. Muehlboeck, P. Mecocci, B. Vellas et al., AddNeuroMed and ADNI: Similar patterns of Alzheimer's atrophy and automated MRI classification accuracy in Europe and North America, NeuroImage, vol.58, issue.3, pp.818-828, 2011.
DOI : 10.1016/j.neuroimage.2011.06.065

E. Westman, A. Simmons, Y. Zhang, J. Muehlboeck, C. Tunnard et al., Multivariate analysis of MRI data for Alzheimer's disease, mild cognitive impairment and healthy controls, NeuroImage, vol.54, issue.2, pp.1178-1187, 2011.
DOI : 10.1016/j.neuroimage.2010.08.044

L. Velayudhan, R. Killick, H. A. Kinsey, A. Guentert, A. Lynham et al., Plasma transthyretin as a candidate marker for Alzheimer's disease, J Alzheimers Dis, vol.2012, issue.282, pp.369-375

A. Mancinella, M. Mancinella, G. Carpinteri, A. Bellomo, C. Fossati et al., IS THERE A RELATIONSHIP BETWEEN HIGH C-REACTIVE PROTEIN (CRP) LEVELS AND DEMENTIA?, Archives of Gerontology and Geriatrics, vol.49, issue.1, pp.49185-194, 2009.
DOI : 10.1016/j.archger.2009.09.028

B. Kravitz, M. Corrada, and C. Kawas, Elevated C-reactive protein levels are associated with prevalent dementia in the oldest-old, Alzheimer's & Dementia, vol.5, issue.4, pp.318-323, 2009.
DOI : 10.1016/j.jalz.2009.04.1230

G. Davis, N. Baboolal, S. Nayak, and A. Mcrae, Sialic acid, homocysteine and CRP: Potential markers for dementia, Neuroscience Letters, vol.465, issue.3, pp.282-284, 2009.
DOI : 10.1016/j.neulet.2009.09.035

B. Schjeide, C. Schnack, J. Lambert, C. Lill, J. Kirchheiner et al., The Role of Clusterin, Complement Receptor 1, and Phosphatidylinositol Binding Clathrin Assembly Protein in Alzheimer Disease Risk and Cerebrospinal Fluid Biomarker Levels, Archives of General Psychiatry, vol.68, issue.2, pp.207-213, 2011.
DOI : 10.1001/archgenpsychiatry.2010.196

J. Lambert, S. Heath, G. Even, D. Campion, K. Sleegers et al., Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease, Nature Genetics, vol.12, issue.10, pp.411094-1099, 2009.
DOI : 10.1038/ng.439

L. Parnetti, S. Amici, A. Lanari, C. Romani, C. Antognelli et al., Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors, Neurological Sciences, vol.23, issue.0, pp.95-96, 2002.
DOI : 10.1007/s100720200086

M. Ewers, Z. Zhong, K. Burger, A. Wallin, K. Blennow et al., Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease, Brain, pp.1311252-1258, 2008.

S. Kassner, G. Bonaterra, E. Kaiser, W. Hildebrandt, J. Metz et al., Novel Systemic Markers for Patients with Alzheimer Disease? ??? A Pilot Study, Current Alzheimer Research, vol.5, issue.4, pp.358-366, 2008.
DOI : 10.2174/156720508785132253

F. Blasi and N. Sidenius, The urokinase receptor: Focused cell surface proteolysis, cell adhesion and signaling, FEBS Letters, vol.1778, issue.9, pp.1923-1930, 2010.
DOI : 10.1016/j.febslet.2009.12.039

H. Smith and C. Marshall, Regulation of cell signalling by uPAR, Nature Reviews Molecular Cell Biology, vol.14, issue.1, pp.23-36
DOI : 10.1038/nrm2821

F. Blasi and P. Carmeliet, uPAR: a versatile signalling orchestrator, Nature Reviews Molecular Cell Biology, vol.190, issue.12, pp.932-943, 2002.
DOI : 10.1038/nrm977

J. Davis, M. Wagner, W. Zhang, F. Xu, and W. Van-nostrand, Amyloid betaprotein stimulates the expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in human cerebrovascular smooth muscle cells, J Biol Chem, issue.21, pp.27819054-19061, 2003.

D. Walker, L. Lue, and T. Beach, Increased expression of the urokinase plasminogen-activator receptor in amyloid ?? peptide-treated human brain microglia and in AD brains, Brain Research, vol.926, issue.1-2, pp.69-79, 2002.
DOI : 10.1016/S0006-8993(01)03298-X

M. Asahina, Y. Yoshiyama, and T. Hattori, Expression of matrix metalloproteinase-9 and urinary-type plasminogen activator in Alzheimer's disease brain, Clin Neuropathol, vol.20, issue.2, pp.60-63, 2001.

. Greco, Alzheimer's disease biomarker discovery using in silico literature mining and clinical validation, Journal of Translational Medicine, vol.10, issue.1, p.217, 2012.
DOI : 10.1074/jbc.M301398200